Hematology

For patients with COVID-19, the combination of the disease and preexisting atrial arrhythmias may create a pathologic synergy that significantly increases the risk for major adverse cardiac events and death.

The research team described how approximately 12 minutes of acute cardiopulmonary exercise affected more than 80% of circulating metabolites, including pathways linked to a wide range of favorable health outcomes, thus identifying potential mechanisms that could contribute to a better understanding of the cardiometabolic benefits of exercise.

A review of the biologics license application for lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

The researchers examined the health records of more than 1100 adults, who had an average age of 45 years, were 52% female, and who are participants in the ongoing Childhood Determinants of Adult Health study.

Individuals who regularly consume chili peppers may live longer and may have a significantly reduced risk of dying from cardiovascular disease or cancer

Centhaquine was found to improve survival in those with hypovolemic shock.

A CDC report reveals that approximately 9% of teens between the ages of 15 and 19 received an opioid prescription in 2018.

In a study published in Physics of Fluids, modeling conducted in June 2020 showed strains of COVID-19 on surfaces—such as metal, leather, and plastic—were killed in as little as 30 seconds of treatment with argon-fed, cold atmospheric plasma.

Higher fitness levels reduced the risk of developing atrial fibrillation by up to 50% in a study of Black male veterans.

Statin use in certain patients may lead to increased muscle pain so severe it can affect adherence.

Janssen Pharmaceutical Companies submitted a supplemental New Drug Application (sNDA) to the FDA to expand the use of rivaroxaban in patients with peripheral artery disease.

Patients recently diagnosed with cancer are significantly more likely to quit smoking and remain tobacco-free if they receive frequent phone counseling over an extended period of time.

The study found patients who received radiation 34 days or fewer before their infusion with CART-B cell maturation antigen (BCMA) cells did not have worse rates of severe cytokine release syndrome or neurotoxicity, which are 2 common adverse effects of the cellular therapy.

Researchers from 2 independent studies have found that SARS-CoV-2 may be more capable of infecting human cells due to the virus’ spike protein recognizing and binding to neuropilin-1.

Angiotensin receptor II blockers are often prescribed to control hypertension or for heart failure, kidney failure, or following a heart attack.

Earlier studies have suggested that statins can potentially benefit some forms of cancer and dementia, meaning investigators could design drugs based on these beneficial effects.

Data show that children with cancer who are experiencing neighborhood poverty and rely on public health insurance have an increased risk of death with stem cell treatment.

Pharmacists assist their colleagues in drug preparation, ensure that patients understand treatment expectations, manage adverse effects, and provide monitoring and follow-up to improve quality of life and patient outcomes.

Since atypical hemolytic uremic syndrome has a poor prognosis, it is essential that diagnosis occurs rapidly, and treatment is started as soon as possible to prevent progression to endstage renal disease.

T-cells may offer immunity from COVID-19 and may be a more effective prevention option than a vaccine for patients with certain underlying conditions.

The objective for researchers in the new study was to determine whether the findings were generalizable in other populations by conducting a similar analysis in the United States, focusing on death from cardiovascular disease.

The study is one of the largest to ever use nutritional biomarkers to investigate bioactive compounds in lowering blood pressure.

The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.

The FDA action was based on results from the Phase 3 CheckMate -9ER trial evaluating nivolumab in combination with cabozantinib compared with sunitinib among patients with previously untreated advanced RCC.

Venetoclax was granted accelerated approval in November 2018, as well as priority review, breakthrough designation, and orphan drug designation.